PCSA

Processa is a clinical-stage biopharma with zero product revenue in any year on record (FY2021–FY2025) and a $101M accumulated deficit. Every dollar of value rests on unapproved pipeline candidates — NGC-Cap (PCS6422/capecitabine) and NGC-Iri (PCS11T), plus earlier-stage PCS12852 and PCS499 — none of which has demonstrated efficacy sufficient for FDA approval. Management itself states its financials 'contain a statement regarding a substantial doubt about our ability to continue as a going concern,' and the risk factors lead with the need to 'raise additional capital to complete the development efforts for NGC-Cap and/or NGC-Iri.' This is the textbook profile of a company whose equity is a lottery ticket on clinical readouts, not an investable business.

The balance sheet makes the timing acute. FY2025 cash of $5.54M against operating cash burn of $11.4M implies roughly six months of runway — the company must raise, and it has already filed a $50M S-3 shelf and an active ATM sales agreement to do so. With only 2.66M shares outstanding after a share count that fell 49.5% YoY (a reverse split), the diluted loss is $10.36 per share and ROE is -243%. Dilution from the ATM is not a risk, it is the stated funding mechanism, and it will fall on existing holders at whatever price the market offers.